tiprankstipranks
Entrada Therapeutics Inc (TRDA)
NASDAQ:TRDA
US Market
TRDA
Entrada Therapeutics Inc
RESEARCH TOOLSreports

Entrada Therapeutics Inc (TRDA) Stock News & Sentiment

149 Followers
Advancing Exon-Skipping and Undervalued DM1 Collaboration Underscore Buy Rating on Entrada Therapeutics
Premium
Ratings
Advancing Exon-Skipping and Undervalued DM1 Collaboration Underscore Buy Rating on Entrada Therapeutics
1M ago
TRDA
Advancing DMD and DM1 Pipeline Positions Entrada for Multiple Near‑Term Catalysts and Upside Potential
Premium
Ratings
Advancing DMD and DM1 Pipeline Positions Entrada for Multiple Near‑Term Catalysts and Upside Potential
2M ago
TRDA
Entrada Therapeutics: Advancing ENTR-601-44 Positions Platform for Best-in-Class Dystrophin Restoration and Attractive Risk/Reward
Premium
Ratings
Entrada Therapeutics: Advancing ENTR-601-44 Positions Platform for Best-in-Class Dystrophin Restoration and Attractive Risk/Reward
2M ago
TRDA
Entrada Therapeutics: Advancing DMD and DM1 Pipeline with Emerging Ophthalmology Assets Supports Buy Rating and $20 Target
Premium
Ratings
Entrada Therapeutics: Advancing DMD and DM1 Pipeline with Emerging Ophthalmology Assets Supports Buy Rating and $20 Target
3M ago
TRDA
Entrada Therapeutics highlights RNA pipeline progress and outlook
Premium
Company Announcements
Entrada Therapeutics highlights RNA pipeline progress and outlook
3M ago
8K
TRDA
Entrada Therapeutics Reports Increased Losses Amid R&D Expansion
Premium
Company Announcements
Entrada Therapeutics Reports Increased Losses Amid R&D Expansion
5M ago
TRDA
Promising Outlook for Entrada Therapeutics: Strategic Advancements in DMD and DM1 with Novel EEV Platform
Premium
Ratings
Promising Outlook for Entrada Therapeutics: Strategic Advancements in DMD and DM1 with Novel EEV Platform
5M ago
TRDA
More TRDA News >

TRDA News on the Web

Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA) and Viridian Therapeutics (VRDN)
TipRanks News
Neutral
Entrada Therapeutics price target raised to $23 from $21 at Oppenheimer
TipRanks News
Bullish
Insider Sell Alert: Kory Wentworth Sells Shares of Entrada Therapeutics Inc (TRDA)
GuruFocus News
Bearish
Entrada Therapeutics initiated with an Overweight at Cantor Fitzgerald
TipRanks News
Bullish
Analysts Have Conflicting Sentiments on These Healthcare Companies: Entrada Therapeutics Inc (TRDA), Apellis Pharmaceuticals (APLS) and MoonLake Immunotherapeutics (MLTX)
TipRanks News
Bullish
Entrada Therapeutics management to meet with Oppenheimer
TipRanks News
Bullish
Analysts Are Bullish on These Healthcare Stocks: Entrada Therapeutics Inc (TRDA), CG Oncology, Inc. (CGON)
TipRanks News
Bullish
Insider Sell Alert: Nathan Dowden Sells Shares of Entrada Therapeutics Inc (TRDA)
GuruFocus News
Bearish

News Score - Last 7 Days

Neutral
TRDA
Sector Average
Media Buzz
This Week2 articles
Weekly Average2 articles
News Sentiment
This Week100%
Sector Average68%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is TRDA’s Media Buzz Sentiment?
2 articles about TRDA were published this week. In an average week, 2 articles are published.
    What is TRDA’s weekly average amount of articles?
    In an average week, 2 articles about TRDA are published.
      What is TRDA’s News Sentiment?
      100% of articles about TRDA were positive this week, compared to its sector average of 68%.
        Healthcare Stocks that are Trending in the News
        AORTArtivion
        NBIXNeurocrine
        STAAStaar Surgical
        SLPSimulations Plus
        OWLTOwlet
        Showing the stocks with the most bullish news sentiment over the past week